Sera Prognostics To Present at TD Cowen 45th Annual Health Care Conference

Company Overview - Sera Prognostics Inc. is focused on improving maternal and neonatal health through innovative pregnancy biomarker information [3] - The company aims to provide early, pivotal pregnancy information to enhance the health of mothers and newborns, thereby reducing healthcare delivery costs [3] - Sera Prognostics is headquartered in Salt Lake City, Utah [3] Product Information - The PreTRM® Test is a blood-based biomarker test that predicts the risk of spontaneous preterm birth in asymptomatic singleton pregnancies [5] - This test analyzes proteins in the blood that are highly predictive of preterm birth, allowing for early identification of women at increased risk during weeks 18 to 20 of pregnancy [5] - The PreTRM® Test enables more informed and personalized clinical decisions based on individual risk [5] Industry Context - Preterm birth, defined as any birth before 37 weeks' gestation, is the leading cause of illness and death in newborns [4] - Over the last five years, more than one in ten infants in the United States has been born prematurely [4] - The annual healthcare costs associated with managing complications from prematurity in the U.S. were estimated at approximately $25 billion for 2016 [4]